Cover Image
市場調查報告書

Alvine Pharmaceuticals, Inc. 的產品平台分析

Alvine Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256046
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Alvine Pharmaceuticals, Inc. 的產品平台分析 Alvine Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 25 Pages
簡介

Alvine Pharmaceuticals, Inc. 是總公司設立在美國生物製藥企業,開發麩質過敏症,自體免疫及發炎疾病的治療藥。產品為ALV003蛋白分解酵素,轉谷氨酰胺酶2,HLA阻斷劑,其中ALV003為分解麩質而改變的2種蛋白分解酵素的混合劑,使用於麩質過敏症的治療。

本報告提供Alvine Pharmaceuticals, Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Alvine Pharmaceuticals, Inc. 的基本資料

  • Alvine Pharmaceuticals, Inc. 概要
  • 主要資訊
  • 企業資料

Alvine Pharmaceuticals, Inc. :R&D概要

  • 主要的治療範圍

Alvine Pharmaceuticals, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Alvine Pharmaceuticals, Inc. :開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Alvine Pharmaceuticals, Inc. :藥物簡介

  • latiglutenase
  • Biologic to Antagonize HLA-DQ2 for Celiac Disease
  • Biologics to Inhibit Transglutaminase 2 for Celiac Disease
  • Enzyme for Celiac Disease

Alvine Pharmaceuticals, Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Alvine Pharmaceuticals, Inc. :最近的開發平台資訊

Alvine Pharmaceuticals, Inc. :開發暫停中的計劃

Alvine Pharmaceuticals, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06887CDB

Global Markets Direct's, 'Alvine Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Alvine Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alvine Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Alvine Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Alvine Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Alvine Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Alvine Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Alvine Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Alvine Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Alvine Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alvine Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Alvine Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alvine Pharmaceuticals, Inc. Snapshot
    • Alvine Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Alvine Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Alvine Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Alvine Pharmaceuticals, Inc. - Pipeline Products Glance
    • Alvine Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Alvine Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alvine Pharmaceuticals, Inc. - Drug Profiles
    • latiglutenase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologic to Antagonize HLA-DQ2 for Celiac Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologics to Inhibit Transglutaminase 2 for Celiac Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Enzyme for Celiac Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alvine Pharmaceuticals, Inc. - Pipeline Analysis
    • Alvine Pharmaceuticals, Inc. - Pipeline Products by Target
    • Alvine Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Alvine Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Alvine Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Alvine Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Alvine Pharmaceuticals, Inc. - Dormant Projects
  • Alvine Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alvine Pharmaceuticals, Inc., Key Information
  • Alvine Pharmaceuticals, Inc., Key Facts
  • Alvine Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Alvine Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Alvine Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Alvine Pharmaceuticals, Inc. - Phase II, 2015
  • Alvine Pharmaceuticals, Inc. - Preclinical, 2015
  • Alvine Pharmaceuticals, Inc. - Discovery, 2015
  • Alvine Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Alvine Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Alvine Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Alvine Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Alvine Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Alvine Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Alvine Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Alvine Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Alvine Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Alvine Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Alvine Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top